C7A.022 ICD-10-CM Code: Malignant carcinoid tumor of the ascending colon
C7A.022 maps to CMS-HCC V28 21 (RAF 0.671). Documentation must support MEAT. MEAT criteria · RAF calculator · HCC Buddy coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neuroendocrine tumors (C7A)
C7A.022
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceMalignant carcinoid tumor of the ascending colon
A rare cancer that develops in hormone-producing cells of the ascending colon, the first upward section of the large intestine on the right side of the abdomen.

Buddy Insight
Malignant carcinoid tumor of the ascending colon is a rare neuroendocrine neoplasm of the right colon.
CMS-HCC V28
MappedHCC 21
RAF 0.671
CMS-HCC V24
MappedHCC 12
RAF 0.150
ACA/HHS
MappedHCC 12
Varies by metal level
ESRD/PACE
MappedHCC 12
RAF 0.045
RXHCC
MappedHCC 22
RAF 0.124
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for C7A.022 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C7A.022 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C7A.022 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C7A.022 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C7A.022 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C7A.022 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C7A.022 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C7A.022 an HCC code?
Yes. C7A.022 (Malignant carcinoid tumor of the ascending colon) maps to Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24), with a community non-dual aged RAF of 0.671. It is billable for payment year 2026.
Coder answer: C7A.022 is billable and maps to V28 HCC 21, Lymphoma and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C7A.022
- Description
- Malignant carcinoid tumor of the ascending colon
- HCC (V28)
- HCC 21 — Lymphoma and Other Cancers
- RAF
- 0.671
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work C7A.022 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for C7A.022
For C7A.022 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C7A.022 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C7A.022 is the ICD-10-CM diagnosis code for malignant carcinoid tumor of the ascending colon. A rare cancer that develops in hormone-producing cells of the ascending colon, the first upward section of the large intestine on the right side of the abdomen. C7A.022 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Under the CMS-HCC V28 risk adjustment model, C7A.022 maps to Lymphoma and Other Cancers (HCC 21) with a community, non-dual, aged base RAF weight of 0.671. Under the older CMS-HCC V24 model, C7A.022 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
The ascending colon runs vertically up the right side of the abdomen; distinguish from transverse and descending portions. Because C7A.022 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C7A.022 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •The ascending colon runs vertically up the right side of the abdomen; distinguish from transverse and descending portions
- •Colonic carcinoid tumors may present with abdominal symptoms or be found incidentally during colonoscopy
Clinical Significance
Malignant carcinoid tumor of the ascending colon is a rare neuroendocrine neoplasm of the right colon. Ascending colon carcinoids are part of the midgut neuroendocrine tumor family and may produce serotonin, potentially causing carcinoid syndrome when liver metastases are present. They tend to be diagnosed at a larger size compared to appendiceal carcinoids and carry a more guarded prognosis.
Documentation Requirements
- ✓Pathological confirmation with immunohistochemistry (synaptophysin, chromogranin A)
- ✓Tumor size and depth of invasion — transmural involvement increases metastatic risk
- ✓Ki-67 index and mitotic rate for WHO grading
- ✓Colonoscopic and imaging findings confirming ascending colon location
- ✓Staging workup — CT, octreotide scan, liver assessment
- ✓Surgical procedure performed and margin status
Commonly Confused Codes
- •C18.2: Primary malignant neoplasm of ascending colon; adenocarcinoma uses C18 codes
- •C7A.021: Malignant carcinoid tumor of cecum; the cecum is proximal to the ascending colon
- •C7A.023: Malignant carcinoid tumor of transverse colon; the ascending colon is the right-sided vertical segment
- •D3A.022: Benign carcinoid tumor of ascending colon; verify malignant behavior pathologically

